JV-1-36
| Names | |
|---|---|
| IUPAC name
N-(2-Phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-L-lysinamide
| |
| Other names
Phenylacetyl-(D-Arg2·28,p-chloro-Phe6,Homoarg9·29,Tyr(Me)10,Abu15,Nle27)-Sermorelin
| |
| Identifiers | |
| Properties | |
| C172H284ClN53O41 | |
| Molar mass | 3785.94 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
JV-1-36 is a GHRH antagonist that has been shown to inhibit endometriotic cell proliferation and survival, suggesting that GHRH antagonist may represent promising tools for treatment of endometriosis.[1]
References
[edit]- ^ Annunziata M, Grande C, Scarlatti F, et al. (June 2009). "The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line". Fertil. Steril. 94 (3): 841–849. doi:10.1016/j.fertnstert.2009.03.093. PMID 19524226.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |